Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.42 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 3/20 | 0.39 |
| ▸ | CTSB | P07858 | 3/20 | 0.39 |
| ▸ | CTSH | P09668 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009433 | 0.98 | ZDHHC7 (0.42) | CTSKZDHHC7CTSLCTSBCTSH | |
| SCHEMBL1008660 | 0.98 | ZDHHC7 (0.42) | CTSKZDHHC7CTSLCTSBCTSH | |
| SCHEMBL1009204 | 0.94 | ZDHHC7 (0.42) | CTSKZDHHC7CTSLCTSBCTSH | |
| SCHEMBL11368057 | 0.90 | ZDHHC7 (0.44) | CTSKZDHHC7TSHR | |
| SCHEMBL25762636 | 0.90 | ZDHHC7 (0.44) | CTSKZDHHC7TSHR | |
| SCHEMBL5560916 | 0.84 | METAP2 (0.41) | CTSKTSHRNPSR1 | |
| SCHEMBL1008853 | 0.82 | ZDHHC7 (0.39) | ZDHHC7 | |
| SCHEMBL4418786 | 0.81 | CTSK (0.44) | CTSKCTSLCTSBCTSHTSHR | |
| SCHEMBL1711505 | 0.79 | CTSK (0.43) | CTSKCTSLCTSBCTSHTSHR | |
| SCHEMBL1711503 | 0.79 | CTSK (0.43) | CTSKCTSLCTSBCTSHTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108290849-B | Contrast agents | 伯拉考成像股份公司 | 2022-03-22 | — | — | CN | disclosed |
| US-11021451-B2 | Contrast agents | BRACCO IMAGING S.P.A. (IT) | 2021-06-01 | — | — | US | disclosed |
| EP-3386953-B1 | CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2020-10-21 | — | — | EP | disclosed |
| US-20200325108-A1 | CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2020-10-15 | — | — | US | disclosed |
| US-10781188-B2 | Contrast agents | BRACCO IMAGING S.P.A. (IT) | 2020-09-22 | — | — | US | disclosed |
| US-20180362476-A1 | CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2018-12-20 | — | — | US | disclosed |
| EP-3386953-A1 | CONTRAST AGENTS | Bracco Imaging SpA (IT) | 2018-10-17 | — | — | EP | disclosed |
| WO-2017098038-A1 | CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2017-06-15 | — | — | WO | disclosed |
| US-20160009735-A1 | Glucokinase Activators | TAKEDA PHARMACEUTICAL (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009735-A1 | Glucokinase Activators | TAKEDA PHARMACEUTICAL (US) | 2016-01-14 | — | — | US | disclosed |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| WO-2009127544-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
| EP-2091947-A2 | GLUCOKINASE ACTIVATORS | Takeda San Diego, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20090105255-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090105255-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090105255-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2009-04-23 | — | — | US | disclosed |
| WO-2008079787-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079787-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021451-B2 | Contrast agents | SLC39A14, ABCB7, SLC40A1 | CTSK 2491/4885ZDHHC7 3644/4885CTSL 3350/4885 |
| US-20160009735-A1 | Glucokinase Activators | GCK, GCKR, GALK1 | CTSK 100/4885ZDHHC7 2186/4885CTSL 905/4885 |
| US-20200325108-A1 | CONTRAST AGENTS | SLC39A14, ABCB7, SLC40A1 | CTSK 2491/4885ZDHHC7 3644/4885CTSL 3350/4885 |
| US-20180362476-A1 | CONTRAST AGENTS | SLC30A5, SLC39A14, ABCB7 | CTSK 2739/4885ZDHHC7 3544/4885CTSL 3442/4885 |
| US-10781188-B2 | Contrast agents | SLC39A14, ABCB7, SLC40A1 | CTSK 2491/4885ZDHHC7 3644/4885CTSL 3350/4885 |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | GCK, GCKR, PDXK | CTSK 329/4885ZDHHC7 2486/4885CTSL 1894/4885 |
| US-20090105255-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | CTSK 100/4885ZDHHC7 2433/4885CTSL 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.